


## Claims

1. A compound of formula (I):



wherein:

Y is phenyl, unsubstituted or substituted with one, two or three substituents;

R<sup>1</sup> is selected from hydrogen, C<sub>1-6</sub> alkyl, C<sub>3-6</sub> cycloalkyl, or halosubstituted C<sub>1-6</sub> alkyl;


R<sup>2</sup> is (CH<sub>2</sub>)<sub>m</sub>R<sup>3</sup> where m is 0 or 1;

or R<sup>1</sup> and R<sup>2</sup> together with N to which they are attached form an optionally substituted 4- to 8- membered non-aromatic heterocyclyl ring;

R<sup>3</sup> is a 4- to 8- membered non-aromatic heterocyclyl group, a C<sub>3-8</sub> cycloalkyl group, a straight or branched C<sub>1-10</sub> alkyl, a C<sub>2-10</sub> alkenyl, a C<sub>3-8</sub> cycloalkenyl, a C<sub>2-10</sub> alkynyl, or a C<sub>3-8</sub> cycloalkynyl any of which can be unsubstituted or substituted or R<sup>5</sup>;

R<sup>4</sup> is selected from hydrogen, C<sub>1-6</sub> alkyl, C<sub>3-6</sub> cycloalkyl, or halosubstituted C<sub>1-6</sub> alkyl, COCH<sub>3</sub>, or SO<sub>2</sub>Me;

R<sup>5</sup> is



wherein p is 0, 1 or 2, and X is CH<sub>2</sub>, O, or S;

R<sup>6</sup> is a substituted or unsubstituted (C<sub>1-6</sub>)alkyl or chloro and R<sup>10</sup> is hydrogen or R<sup>10</sup> is a substituted or unsubstituted (C<sub>1-6</sub>)alkyl or chloro and R<sup>6</sup> is hydrogen;

R<sup>7</sup> is OH, C<sub>1-6</sub>alkoxy, NR<sup>8a</sup>R<sup>8b</sup>, NHCOR<sup>9</sup>, NHSO<sub>2</sub>R<sup>9</sup> or SOqR<sup>9</sup>;

R<sup>8a</sup> is H or C<sub>1-6</sub>alkyl;


R<sup>8b</sup> is H or C<sub>1-6</sub>alkyl;

R<sup>9</sup> is C<sub>1-6</sub>alkyl;

q is 0, 1 or 2;

or a pharmaceutically acceptable derivative thereof.

2. A compound as claimed in claim 1 of formula (Ia):



$R^1$  is selected from hydrogen,  $C_{1-6}$  alkyl,  $C_{3-6}$  cycloalkyl, or halosubstituted  $C_{1-6}$  alkyl;


$R^2$  is  $(CH_2)_m R^3$  where  $m$  is 0 or 1;

10 or  $R^1$  and  $R^2$  together with N to which they are attached form a non-aromatic heterocyclyl ring selected from azetidiny, pyrrolidiny, morpholiny, piperaziny, piperidiny, tetrahydropyridiny, azapine, oxapine, azacyclooctanyl, azaoxacyclooctanyl and azathiacyclooctanyl, any of which can be unsubstituted or substituted with 1, 2 or 3 substituents selected from;  $C_{1-6}$  alkyl,  $C_{1-6}$  alkoxy, hydroxy, cyano, halo, sulfonyl, methylsulfonyl,  $NR^{8a}R^{8b}$ ,  $CH_2$ phenyl,  $NHCOCH_3$ , ( $=O$ ),  $CONHCH_3$  and  $NHSO_2CH_3$ ;

15  $R^3$  is 2- or 3- azetidiny, oxetanyl, thioxetanyl, thioxetanyl-s-oxide, thioxetanyl-s,s-dioxide, dioxalanyl, pyrrolidiny, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydrothiophenyl-s,s-dioxide, morpholiny, piperidiny, piperaziny, tetrahydropyranyl, tetrahydrothiopyranyl, thiomorpholiny, thiomorpholiny-s,s-dioxide, tetrahydropyridiny, dioxanyl, tetrahydro-thiopyran 1,1 dioxide, azapine, oxapine, azacyclooctanyl, azaoxacyclooctanyl, azathiacyclooctanyl, oxacyclooctanyl, thiacyclooctanyl, a  $C_{3-8}$  cycloalkyl group, a straight or branched  $C_{1-10}$  alkyl, a  $C_{2-10}$  alkenyl, a  $C_{3-8}$  cycloalkenyl, a  $C_{2-10}$  alkynyl, or a  $C_{3-8}$  cycloalkynyl or  $R^5$ ; any of which can be unsubstituted or substituted with 1, 2 or 3 substituents selected from  $C_{1-6}$  alkyl,  $C_{1-6}$  alkoxy, hydroxy, cyano, halo, sulfonyl, methylsulfonyl,  $NR^{8a}R^{8b}$ ,  $CH_2$ phenyl,  $NHCOCH_3$ , ( $=O$ ),  $CONHCH_3$  and  $NHSO_2CH_3$ ;

25  $R^4$  is selected from hydrogen,  $C_{1-6}$  alkyl,  $C_{3-6}$  cycloalkyl, or halosubstituted  $C_{1-6}$  alkyl,  $COCH_3$ , or  $SO_2Me$ ;

$R^5$  is



30 wherein  $p$  is 0, 1 or 2, and  $X$  is  $CH_2$ , O or S;

$R^6$  is a substituted or unsubstituted  $(C_{1-6})$ alkyl or chloro and  $R^{10}$  is hydrogen or  $R^{10}$  is a substituted or unsubstituted  $(C_{1-6})$ alkyl or chloro and  $R^6$  is hydrogen;

$R^7$  is OH,  $C_{1-6}$ alkoxy,  $NR^{8a}R^{8b}$ ,  $NHCOR^9$ ,  $NHSO_2R^9$  or  $SOqR^9$ ;

$R^{8a}$  is H or  $C_{1-6}$ alkyl;

35  $R^{8b}$  is H or  $C_{1-6}$ alkyl;

$R^9$  is  $C_{1-6}$ alkyl;

$R^{11}$  is  $C_{1-6}$  alkyl, halosubstituted  $C_{1-6}$  alkyl,  $C_{1-6}$  alkoxy, hydroxy, cyano, halo,  $C_{1-6}$ alkylsulfonyl group,  $-CONH_2$ ,  $-NHCOCH_3$ ,  $-COOH$ , halosubstituted  $C_{1-6}$  alkoxy  $SO_2NR^{8a}R^{8b}$  or  $C_{1-6}$  alkynyl;

40  $q$  is 0, 1 or 2;

d is 0,1, 2, or 3;  
or a pharmaceutically acceptable derivative thereof.

3. A compound as claimed in claim 1 or 2 wherein R<sup>1</sup> is hydrogen.
- 5 4. A compound as claimed in any preceding claim wherein R<sup>4</sup> is C<sub>1-8</sub> alkyl or hydrogen.
- 10 5. A compound as claimed in any preceding claim wherein R<sup>6</sup> is *t*-butyl, isopropyl or CF<sub>3</sub>.
6. A pharmaceutical composition comprising a compound as claimed any preceding claim or a pharmaceutically acceptable derivative thereof .
- 15 7. A pharmaceutical composition as claimed in claim 6 further comprising a pharmaceutical carrier or diluent thereof.
- 20 8. A method of treating a human or animal subject suffering from a condition which is mediated by the activity of cannabinoid 2 receptors which comprises administering to said subject a therapeutically effective amount of a compound of formula (I) as claimed in any one of claims 1 to 5 or a pharmaceutically acceptable derivative thereof.
- 25 9. A method of treatment as claimed in claim 8 wherein the condition is an immune disorder, an inflammatory disorder, pain, rheumatoid arthritis, multiple sclerosis, osteoarthritis or osteoporosis.